Research
Analysis of drug coverage before and after the implementation of Canada’s Common Drug Review
John-Michael Gamble, Daniala L. Weir, Jeffrey A. Johnson and Dean T. Eurich
CMAJ November 22, 2011 183 (17) E1259-E1266; DOI: https://doi.org/10.1503/cmaj.110670
John-Michael Gamble
BScPharm MSc
Daniala L. Weir
Jeffrey A. Johnson
PhD
Dean T. Eurich
PhD
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Analysis of drug coverage before and after the implementation of Canada’s Common Drug Review
John-Michael Gamble, Daniala L. Weir, Jeffrey A. Johnson, Dean T. Eurich
CMAJ Nov 2011, 183 (17) E1259-E1266; DOI: 10.1503/cmaj.110670
Jump to section
Related Articles
Cited By...
- Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations
- An analysis of redactions in Canadas Common Drug Review Clinical Review Reports and how they relate to the patients voice
- Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study
- Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance